EP2470147A1 - Poche de stockage de solution therapeutique - Google Patents
Poche de stockage de solution therapeutiqueInfo
- Publication number
- EP2470147A1 EP2470147A1 EP10752431A EP10752431A EP2470147A1 EP 2470147 A1 EP2470147 A1 EP 2470147A1 EP 10752431 A EP10752431 A EP 10752431A EP 10752431 A EP10752431 A EP 10752431A EP 2470147 A1 EP2470147 A1 EP 2470147A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- membrane
- solution
- storage bag
- compartment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D29/00—Sacks or like containers made of fabrics; Flexible containers of open-work, e.g. net-like construction
- B65D29/02—Sacks with laminated or multiple walls
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D47/00—Closures with filling and discharging, or with discharging, devices
- B65D47/04—Closures with discharging devices other than pumps
- B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1462—Containers with provisions for hanging, e.g. integral adaptations of the container
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2205/00—General identification or selection means
- A61J2205/10—Bar codes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2205/00—General identification or selection means
- A61J2205/30—Printed labels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2203/00—Decoration means, markings, information elements, contents indicators
- B65D2203/02—Labels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D33/00—Details of, or accessories for, sacks or bags
- B65D33/004—Information or decoration elements, e.g. level indicators, detachable tabs or coupons
Definitions
- the present invention relates to a therapeutic solution storage bag and a method of manufacturing such a storage bag.
- therapeutic solution any type of product in liquid form used for a therapeutic purpose.
- blood components in liquid form for example blood plasma, platelets, or a packed cell.
- blood plasma derivatives for example albumin or an immunoglobulin.
- It can also be medication solutions, or even nutritional solutions.
- glucose solution for example at 5%, G5, or else saline solutions, especially isotonic solutions or a Ringer's solution.
- Storage bags like glass bottles, are subject to very demanding regulations, particularly with regard to their manufacture and traceability.
- the pockets must have an inscription providing information about the solution, safety elements such as, the name of the manufacturer, the expiry date, the lot number, the recipient or the name of the patient, including traceability of the solution.
- the pouches are usually packaged and sent to hospitals or to any recipient who can administer the solution to a patient. The patient can himself be a recipient and administer the solution.
- the bags currently on the market have an inscription carried directly on a membrane delimiting a receiving compartment of the solution, as is the case of the Flexbumin ® flexible pouch, flexible pouch containing human albumin, manufactured and marketed, particularly in Sweden, by Baxter.
- the inscription can also be worn by gluing a label on which it was previously written, printed and / or stamped, or by gluing a blank label on which one writes and / or stamps thereafter.
- the inscription can also be worn directly on the membrane by handwriting typically with a pen or pen or ink pad. This is particularly the case when the bag is used to administer an infusion to a patient. It may be that during the course of administration the contents of the bag are modified, for example by the addition of a drug, and that the nursing staff then wear a marker indicating the modification in question. quantity to be administered or the administration time to be respected.
- Patent application WO 02/072429 describes a flexible polymer pouch for storing a solution of peptides and / or proteins, as well as a method for introducing such a solution into a flexible polymer container.
- the manner of carrying an inscription on the storage bag is not mentioned in this document.
- US Patent 4,654,240 discloses a laminated film material for a flexible pouch capable of storing a product to be maintained and extracted under sterile conditions. The bag is optionally steam sterilized. The way of carrying an inscription on the storage pocket is not mentioned in this document either.
- a solution to reduce the risk of contamination in the case where the inscription is carried on the membrane is to use a particular ink whose molecules pass through the membrane more difficult.
- such an ink is expensive.
- this solution does not sufficiently reduce the risk of contamination because ink molecules continue to cross the membrane, and because the membrane can still be damaged.
- this solution does not respond to the risk of contamination related to the inscription carried by sticking a label. There is therefore a need to enhance the safety of the batches of therapeutic solution.
- the Applicant has surprisingly developed by the present invention a storage bag of a therapeutic solution, providing an improvement in the safety of the therapeutic solution, and allowing to carry an inscription while reducing the risk of contamination. .
- the invention proposes a therapeutic solution storage pouch comprising at least one solution-receiving compartment delimited by a membrane.
- the bag further comprises at least one appendage in the extension of the membrane and having a registration area.
- the storage bag further has one or more of the following features:
- the membrane is transparent
- the membrane comprises one or more orifices
- the membrane is a multilayer membrane
- the pocket further comprises a sealed and / or opaque external envelope
- the outer envelope consists of a multilayer film containing an aluminum layer surrounded on both sides by a layer of plastic;
- the compartment has a capacity of maximum capacity of between one milliliter and one liter, advantageously between 5 and 500 milliliters, advantageously between 10 and 500 milliliters, more advantageously between 20 and 200 milliliters, and still more advantageously between 50 and 100 milliliters;
- the compartment contains a therapeutic solution, in particular albumin or an immunoglobulin, preferably normal immunoglobulin G (IGNG).
- IGNG normal immunoglobulin G
- the invention also proposes a method of manufacturing a therapeutic solution storage bag, previously described, comprising the steps of:
- the invention also proposes a method of manufacturing a therapeutic solution storage bag whose compartment contains a therapeutic solution or albumin or an immunoglobulin, previously described, comprising the steps of:
- the method further comprises a step of irradiating the storage bag before step (i) filling.
- FIG. 1 a view of a storage bag according to a preferred embodiment of the invention.
- the invention relates to a therapeutic solution storage bag.
- the pocket comprises at least one receiving compartment of the solution.
- the pocket also includes a membrane, the compartment being the space delimited by the membrane.
- the pocket also comprises at least one appendix in the extension of the membrane and having a registration area.
- the membrane may consist of a single piece folded and / or welded so as to define the compartment.
- the membrane may also consist of an assembly of several parts welded together so as to define the compartment.
- the compartment allows the reception of a volume of solution for its storage.
- the registration area allows for an inscription providing information relating to the pocket.
- This information relates in a non-limiting manner to one or more of the following: the content of the solution, the producer of the solution and its logo, the seller of the solution, the concentration of the solution, information on the hospital or the institution or the recipient, the name of the patient.
- the information can be coded by presenting for example in the form of a barcode or datamatrix (matrix consisting of juxtaposed points or squares, equivalent to the barcode in two dimensions).
- the inscription may be carried, in a non-limiting manner, by writing by hand with ink on the appendix, by gluing or stapling a label on which was previously printed, handwritten, or stamped, or by gluing or stapling a blank label on which the inscription is subsequently handwritten or stamped.
- the registration area is on the appendage in the extension of the membrane, it is possible to wear an inscription on the pocket with a reduced risk of contamination. Indeed, carrying an inscription on an area of an appendage in the prolongation of the membrane and not directly on the membrane in contact with the solution reduces the risk of deterioration of the membrane and migration of contaminating molecules towards the membrane. compartment.
- mirage refers to a visual inspection operation on containers intended to detect any contamination or other defects, such as particles, filling defects, pieces of plastic.
- Figure 1 shows a view of a storage pocket 10 according to a preferred embodiment of the invention.
- the bag 10 comprises a compartment 11 for receiving solution delimited by a membrane 12.
- the bag 10 also comprises an appendage 13 in the extension of the membrane 12.
- the appendix 13 is projecting of the membrane 12, but not necessarily in the axis or in the plane of the membrane 12.
- the appendix 13 comprises an inscription zone 14, which is separated from the membrane 12 in a separate zone. An inscription providing information relating to the pocket can therefore be worn with a reduced risk of contamination.
- the membrane 12 is transparent. This makes it possible to examine visually or by any other equivalent means a solution stored in the pocket 10. In fact, carrying an inscription on an area of an appendix in the extension of a transparent membrane and not directly on the membrane improves the effectiveness of the mirage, especially at the time of filling, because the membrane is blank of any impression, but also at the time of use by hospital staff to check the clarity of the solution to be infused.
- the storage pockets on the market have an inscription on the membrane.
- an inscription on the membrane is an inconvenience for the nursing staff when it wishes to take the precautionary measures mentioned above.
- An inscription on the membrane is also an inconvenience when the caregiver wishes to check the volume of solution contained in the compartment 11, for example to verify that an infusion is proceeding correctly.
- the presence of this inscription on the membrane is a hindrance during the operation of mirage therapeutic solutions.
- the inscription zone 14 is separated from the transparent membrane 12. No registration thus hinders the eye, which facilitates and consequently accelerates the work of the nursing staff. The facilitation of the work of the nursing staff is of great importance especially in emergency care.
- the membrane 12 is not transparent, but rather opaque in order to protect the solution from light irradiation. This can be the case when the solution stored in the bag 10 is not directly administered, but taken for example by means of a syringe before being administered. In this case, the precautionary measures mentioned above can be taken after taking the solution from the syringe. It is also possible that the solution is administered from the bag 10 in this case of the opaque membrane.
- the membrane 12 of Figure 1 comprises an orifice 16.
- the orifice 16 allows the injection into the compartment 11 of a solution for storage.
- the orifice 16 also allows the flow of a solution stored out of the compartment 11 for its administration by infusion to a patient.
- the orifice 16 is connected to a conduit, not shown, administering the solution to a patient.
- the conduit connects the compartment to a vein of the patient.
- the orifice 16 may also be used as an access route for taking a certain amount of solution using a syringe or other sampling tool.
- the orifice 16 may also be used as an access route for the injection of a given quantity of a medicament, for example for the treatment of cancer patients, for whom a solution of active principle is injected. in the pocket, possibly after reconstitution by the medical staff.
- the membrane may also include several orifices.
- the membrane may comprise two orifices: a first orifice for injecting the solution into the compartment for its storage, and a second orifice for the flow of the solution out of the compartment for its administration to a patient.
- a pocket comprising a plurality of orifices makes it possible to add elements to a solution stored in the pocket via the first orifice at the same time as the solution flows through the second orifice during the infusion.
- the orifice 16 is advantageously located in an area opposite the appendix 13 with respect to the compartment 11.
- the appendix 13 may be provided with a fastening member 17, as is the case in the embodiment of Figure 1.
- the fastening member 17 is constituted by a hole through the appendix 13. This configuration is however not limiting. Indeed, a different number of holes can be made.
- other types of attachment members such as a magnet, a hook protruding from the appendix 13 or an adhesive can be used.
- the fastening member 17 makes it possible to suspend the pocket at a support preferably located at a height. Since the orifice 16 is situated in an area opposite the appendix 13 with respect to the compartment 11, the suspension of the pocket 10 by the fastening member 17 allows the solution to flow out of the compartment 11 through the orifice 16 under the effect of gravity.
- the bag 10 can thus be suspended over a patient and be used as an infusion bag.
- the term "zone opposite to the appendix to the compartment" means the zone of the membrane 12 the lowest when the bag is suspended by a fastening member 17 of Appendix 13.
- the orifice or the orifices intended for the flow of the solution out of the compartment 11 are situated in an area opposite to the appendix 13 with respect to the compartment 11, which ensures flow of the solution under the effect of gravity.
- the flow of the solution is by means of a pump, or even by compression of the compartment 11, especially in the infusion assisted infusion mode.
- the orifice 16 may as well be located in an opposite zone to the appendix 13 with respect to the compartment 11 as in another zone, the gravity being no longer necessary to ensure the flow of the solution.
- the orifice 16 is provided with a closure member 18. This closure member makes it possible to prevent an undesired flow of the solution.
- the orifice 16 is provided with the closure member 18, for example by welding a fixed part 19 of the closure member 18 on the contour of the orifice 16.
- removing a removable portion 20 of the closure member 18 by breaking a breakable joint between the fixed portion 19 and the removable portion 20.
- the joint is breakable by a rotation of the removable portion 20 relative to the fixed portion 19. This mechanism is known as the "twist-off".
- a breakable joint allows rapid use of the pocket 10.
- the closure member 18 may be closed by the removable portion 20, or by another element, although it has been previously removed using for example a screw mechanism.
- This configuration makes it possible to close the orifice 16 despite a first beginning of flow of the solution.
- This configuration is of interest for example when it is desired to temporarily interrupt an infusion.
- the membrane 12 is preferably made of a flexible material. It is advantageously a plastic material. PVC, polyethylene, polypropylene or any other material commonly used for producing flexible bags can be used. The thickness of the films is classic.
- the membrane is made from polypropylene.
- the flexibility of the pocket 10 allows easier storage of the pocket 10, a simpler waste disposal, as well as greater ease of use compared to rigid bottles.
- the membrane being made of a flexible material, it is unbreakable. This avoids the problems of decontamination related to the use of glass vials.
- the membrane 12 may also consist of multilayer films, in particular three-layer films, the materials constituting the various layers having their own functions, for example a barrier (for example an oxygen barrier or an infusion product), a support, a binder between two layers etc.
- a barrier for example an oxygen barrier or an infusion product
- a use of several layers makes it possible to further reduce the risk of contamination and to increase the resistance capabilities of the membrane 12, in particular to physical stresses and beta-ray irradiations.
- a use of three layers makes it possible to compromise between an increase in the resistance and the preservation of the transparency of the membrane 12.
- the bag may also be placed in a removable outer envelope preferably waterproof.
- This outer shell has the advantage of constituting a physical barrier for the loss of water.
- this outer envelope if it is opaque, protects the solution from denaturations that could be induced by light.
- Such an outer envelope is particularly advantageous in the case where the solution stored in the bag 10 is albumin or an immunoglobulin for example, particularly sensitive to light.
- the immunoglobulin may be manufactured according to the method described in the documents FR-2824568-A1 and FR-2895263-A1. It may be an intravenous immunoglobulin G (IVIG).
- IVIG intravenous immunoglobulin G
- the outer casing may also consist of multilayer films, in particular three-layer films, the constituent materials of the different layers having their own functions, for example that of blocking the light, or that of ensuring a seal.
- the outer shell can be made of aluminum or plastic or a mixture of both.
- the outer casing may be thermoformed around the storage pocket 10.
- the outer envelope consists of a multilayer film containing an aluminum layer surrounded on both sides by a layer of plastic, for example polypropylene, which makes it gives special resistance to shocks, and is a barrier to light.
- the outer envelope consists of a polyethylene layer, an aluminum layer and a polypropylene layer.
- a storage bag 10 according to the invention containing a therapeutic solution is packaged in the outer envelope and then sent to a recipient. Before the use of the pocket 10, the recipient removes the envelope external. Thus, the envelope is an additional protection until it is removed, that is to say until the use of the pocket 10.
- the compartment li has a capacity of maximum capacity of between one milliliter and one liter, advantageously a capacity of maximum capacity of between 5 and 500 milliliters, advantageously between 10 and 500 milliliters, and even more advantageously between 20 and 200 milliliters, advantageously 50 and 100 milliliters.
- the pouch has a capacity of up to 100 milliliters.
- the invention is all the more interesting that the volume of the compartment 11 is small.
- the smaller the volume of the compartment 11, the smaller the surface of the membrane 12, and the more an inscription on the membrane 12 constitutes an inconvenience.
- the pocket 10 comprises a weld separating the membrane 12 from the appendix 13.
- the weld gives a flexibility to the appendix 13 relative to the compartment 11. This flexibility is useful especially in the case where several pockets storing a solution are stored in a storage box. Since the inscription 15 is on an inscription area 14 of Appendix 13, it is possible to identify a pocket without removing it from the box. The work of the nursing staff is thus facilitated.
- the bag comprises a plurality of solution receiving compartments.
- a membrane defines the compartments, and as in the embodiment of Figure 1, an appendix is in the extension (projecting) of the membrane. Whether in this embodiment not shown or in the previous, several appendices may be in the extension of the membrane, one after the other or next to each other superimposed on each other. This allows to carry several inscriptions on the pocket. This allows for example to carry an inscription per compartment when the pocket comprises several compartments.
- the bag may be provided with a mixer ensuring a mixture of the contents of the different compartments, the mixture then flowing through the orifice.
- the bag may also be provided with an orifice per compartment, a mixture then being provided by a mixer outside the bag.
- the new flexible pouch according to the invention is manufactured by any conventional method of manufacturing flexible pouches.
- the compartment 11 is prepared by welding according to a predefined scheme, by welding a membrane folded over it. same or two separate movies. A cover is provided during the welding, conventionally.
- the welding can also be done in a conventional manner, by heat-sealing or ultrasound.
- the appendage in the extension (projecting) can be attached by welding on an already existing pocket, or on the contrary be obtained directly during manufacture.
- the folded membrane on itself can be continued to form the appendix; it is also possible that the two films are welded together to form the appendix, or that only one of the films is extended to form the appendix.
- the pouch comprises a weld 21 between separating the membrane of the appendix.
- a method of manufacturing a pouch according to the invention may comprise the steps of:
- the pouch packaging process comprises the following steps (after the last step of the pouch manufacturing process):
- the method may include a step of irradiating the storage bag prior to step (i) of filling to sterilize the bag.
- the irradiation is by beta 25 kilograys.
- the method may comprise an intermediate step of pasteurization and / or incubation of the storage bag containing the therapeutic solution, after the step (ii) of capping and before the step (iii) of candling of the storage bag.
- the method comprises an intermediate step of pasteurization and incubation between steps (ii) and (iii).
- the bags tested are in accordance with FIG. 1. These are pockets previously sterilized by ⁇ -irradiation at 25 kGy.
- the membrane 12 is each time transparent, comprises an orifice 16 provided with a twist-off, and is a multilayer membrane consisting of three layers of polypropylene.
- the pouch 12 also comprises an outer casing made of a multilayer film containing an aluminum layer surrounded on either side by a plastic layer.
- the aluminum layer has a thickness of 8 ⁇ m.
- the layers surrounding the aluminum layer are polypropylene terephthalate and polypropylene and have a thickness of 12 microns and 75 microns respectively.
- the outer envelope also called “overpouch” below and in the figures) is thus waterproof and opaque.
- the outer envelope has a width of substantially 160 mm and a length of substantially 270 mm.
- the compartment 11 has a capacity of maximum capacity substantially equal to 100 milliliters.
- information is also pre-printed on labels, and for each pocket, a label is then glued to the registration area (14) of the appendix (13) in the extension of the membrane. (12), and another label is glued to the outer envelope.
- the albumin volume is uniform and is substantially equal to 50 or 100 ml depending on the batch (hereinafter referred to as "lot in 50/100 ml presentation" depending on the capacity of the pockets of the lot in question).
- the pouches are placed in controlled temperature and humidity chambers according to two sets of experimental conditions (ECE):
- T ave before conditioning (T ave), i.e. at the MPVP stage (purified bulk raw material: preheated stabilized albumin),
- the analyzes can be classified according to three categories according to their characterization: qualitative, microbiological or functional.
- the qualitative characterization of the bags focuses on the appearance of the solution (color, degree of opalescence), pH, osmolality, concentration of polymers, aggregates, enzymatic degradation products, sodium , to the potential adsorption of the stabilizer sodium caprylate, to the study of the migration of the highly toxic component of the overpouch aluminum, to the study of the prekallikrein activator, to the observation of the presence of water between the membrane and the overpouch, to the extent of the extractable volume and the weight of the pocket to highlight a possible loss of water during storage.
- Microbiological characterization focuses on sterility.
- the functional characterization focuses on the total protein content (active ingredient content).
- Table I groups the different analyzes and provides for each the method used and the acceptance criterion applied.
- Table II presents the results for a batch in 50ml presentation subjected to the set of conditions ECE 1, the batch being representative.
- the statistical analysis of the results shows the absence of a change in the total protein content as a function of the storage time for all the batches, except for one lot in the 100 ml presentation, for which a decrease in the total protein content is observed over time (existence of a linear regression, p ⁇ 0.05). But this decrease has no impact on the quality of the product, given the conformity of the results obtained at each deadline.
- the results obtained at each deadline are in conformity with the acceptance criteria, with the exception of the sterility of one of the batches in presentation 50 ml to l 6 month deadline.
- Table III presents the results for a batch in 100ml presentation subjected to the set of conditions ECE 2, the batch being representative.
- the statistical analysis of the results shows the absence of a change in the total protein content as a function of the storage time for all the batches, except for one batch in 50 ml presentation and one batch. in presentation 100 ml, for which a decrease in the total protein content is observed over time (existence of a linear regression, p ⁇ 0.05). But this decrease has no impact on the quality of the product, given the conformity of the results obtained at each deadline.
- Example 2 Study of the stability of IgNG (normal immunoglobulin G) 5% stored in test pouches
- Example 1 The notations of Example 1 are repeated.
- the compartments of the bags are filled, manually with the aid of a peristaltic pump, with 50 ml of normal immunoglobulin G (IgNG) 5% manufactured according to the process described in documents FR-2824568-A1 and FR-2895263-A1.
- IgNG normal immunoglobulin G
- ECE 2 ie 40oC ⁇ 2 ° C RH ⁇ 25%).
- glass vials are filled with the same quantity and then stored under the same conditions for reference.
- the analyzes carried out are primarily aimed at verifying the stability of 5% IgNG in the pockets and a possible loss of water during storage, resulting from the diffusion of water through the multilayer membrane of the pocket.
- the analyzes are carried out at TO and after storage for 1 month and 3 months, at 25 ° C. and 40 ° C.
- the methods used are those recommended by the European Pharmacopoeia with regard to the appearance of the solution (degree of opalescence and color), pH, osmolality, total protein content (HPSEC, Anti-Hbs activity, AAC ).
- the fragment assay ( ⁇ 3%), the evaluation of the presence of visible and sub-visible particles, and the tween 80 assay are also performed.
- the aspect of the pocket (flexibility of the membrane, transparency, sealing of the welds, presence of water between membrane and overflow) is also followed.
- extractables and relargables are dosed, according to the "guideline on plastic immediate packaging materials" (CPMP / QWP / 4359/03).
- the study of extractibles is carried out with four extraction matrices (EPPI,
- the substances released from the pockets of IgNG stored for 3 months at 25 ° C and 40 ° C are assayed, based on the results of the extractables study.
- the analyzes are of a semi-quantitative nature, which means that the assays have not been validated beforehand. For techniques requiring extraction (in dichloromethane) of potentially liberated organic compounds (GC / MS and PTVGC / MS), the extraction yield may not be total and the values underestimated. On the other hand, by this semi-quantitative analysis, the response factor of the detected species is assumed equal to that of the internal standard, which is not always accurate.
- Tables IV and V present the results of the stability study of the bags under the conditions ECE 1 and ECE 2 respectively, with each time the result of the references (glass bottles).
- the results show that IgNG is not destabilized in the pockets after 3 months at 25oC and 40oC, compared to storage in a glass bottle.
- the increase in the polymer and fragment content at 40oC is comparable in the pockets and the glass bottles.
- the anti-HBS activity decreases in the same proportions in the pockets and glass vials.
- the use of an all-aluminum overpouch proved effective in preventing water loss. Ig concentration and osmolality do not increase after 3 months of pocket storage with overpouch.
- the main entities detected are Irganox 1076, Irganox 1010, Irganox 1330, Irgafos 168 and Irgafos 168 oxidized at concentrations below the limit of 1 ppm set by the Pharmacopoeia. European, for extractions in aqueous medium and at very low concentrations for extraction in ethanol. In the case of the ⁇ -radiated pockets, volatile compounds by HS-GC / MS and semi-volatile by GC / MS, conventionally known as degradation products or solvents of the polymers have been identified.
- Tables VI and VII below provide the evolution of the content of volatile compounds detected in pockets filled with 5% IgNG, after storage for three months, at 25 ° C. and 40 ° C. respectively. The values are expressed in ppb.
- the values detected are of the order of ppb and close to the detection limit of the method (5 ppb); the differences between the maturities are not significant.
- These are degradation products of polymers, identified in the study of extractables and solvents of the polymers used in the production of the bags. Only the evolution of the ethyl acetate content is significant. While this solvent is not initially detected, it is released after 1 month of storage, at concentrations that remain low.
- Tables VIII and IX below provide the evolution of the content of volatile compounds detected in pockets filled with 5% IgNG, after storage for three months, at 25 ° C. and 40 ° C., respectively. The values are expressed in ppb.
- the use of the aluminum overpouch is effective in blocking the diffusion of water through the membrane.
Landscapes
- Health & Medical Sciences (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15188993.8A EP3000457A1 (fr) | 2009-08-24 | 2010-08-23 | Poche de stockage de solution therapeutique |
PL10752431T PL2470147T3 (pl) | 2009-08-24 | 2010-08-23 | Worek do przechowywania roztworu leczniczego |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0904031A FR2949195B1 (fr) | 2009-08-24 | 2009-08-24 | Poche de stockage de solution therapeutique |
PCT/IB2010/053786 WO2011024112A1 (fr) | 2009-08-24 | 2010-08-23 | Poche de stockage de solution therapeutique |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15188993.8A Division EP3000457A1 (fr) | 2009-08-24 | 2010-08-23 | Poche de stockage de solution therapeutique |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2470147A1 true EP2470147A1 (fr) | 2012-07-04 |
EP2470147B1 EP2470147B1 (fr) | 2015-10-14 |
Family
ID=42062393
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10752431.6A Not-in-force EP2470147B1 (fr) | 2009-08-24 | 2010-08-23 | Poche de stockage de solution therapeutique |
EP15188993.8A Withdrawn EP3000457A1 (fr) | 2009-08-24 | 2010-08-23 | Poche de stockage de solution therapeutique |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15188993.8A Withdrawn EP3000457A1 (fr) | 2009-08-24 | 2010-08-23 | Poche de stockage de solution therapeutique |
Country Status (13)
Country | Link |
---|---|
US (2) | US9468585B2 (fr) |
EP (2) | EP2470147B1 (fr) |
KR (1) | KR20120048693A (fr) |
CN (1) | CN102548522A (fr) |
AU (1) | AU2010288193A1 (fr) |
BR (1) | BR112012004006A2 (fr) |
CA (1) | CA2771736A1 (fr) |
DK (1) | DK2470147T3 (fr) |
ES (1) | ES2558529T3 (fr) |
FR (1) | FR2949195B1 (fr) |
IL (1) | IL218133A0 (fr) |
PL (1) | PL2470147T3 (fr) |
WO (1) | WO2011024112A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9677042B2 (en) | 2010-10-08 | 2017-06-13 | Terumo Bct, Inc. | Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
GR20120100242A (el) * | 2012-05-04 | 2014-01-02 | Micrel Ιατρικα Μηχανηματα Α.Ε., | Αντλια και προγεμισμενος ασκος/σετ αναλγησιας |
WO2014099513A1 (fr) * | 2012-12-19 | 2014-06-26 | Advanced Preservations Technologies, Llc | Dispositif de conservation de produits sanguins dans un milieu gazeux sous pression |
US9617506B2 (en) | 2013-11-16 | 2017-04-11 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
EP3613841B1 (fr) | 2014-03-25 | 2022-04-20 | Terumo BCT, Inc. | Remplacement passif de supports |
EP3198006B1 (fr) | 2014-09-26 | 2021-03-24 | Terumo BCT, Inc. | Alimentation programmée |
DK3047833T3 (en) * | 2015-01-26 | 2017-06-12 | Fresenius Kabi Deutschland Gmbh | Container Closure System |
NO20150142A1 (en) * | 2015-01-30 | 2016-08-01 | Pronova Biopharma Norge As | Enteral feeding device |
WO2017004592A1 (fr) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Croissance cellulaire à l'aide de stimuli mécaniques |
US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
EP3656842A1 (fr) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Expansion de cellules |
JP2020083426A (ja) * | 2018-11-29 | 2020-06-04 | 花王株式会社 | シート材容器 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2693189A (en) * | 1950-12-15 | 1954-11-02 | Abbott Lab | Venoclysis equipment |
US2895475A (en) * | 1956-12-03 | 1959-07-21 | Everett L Cole | Container for collecting, storing and dispensing biological fluids |
FR1348398A (fr) | 1962-09-11 | 1964-01-10 | Carves Simon Ltd | Perfectionnement à l'aération et à la séparation des liquides |
FR1348898A (fr) * | 1963-02-27 | 1964-01-10 | Abbott Lab | Sac pour contenir un liquide destiné à être administré à un patient |
US3905477A (en) * | 1972-03-14 | 1975-09-16 | Union Carbide Corp | Tamperproof pouch label |
ZA73589B (en) * | 1972-03-14 | 1973-10-31 | Union Carbide Corp | Tamperproof puch label |
US3915212A (en) * | 1973-12-10 | 1975-10-28 | Abbott Lab | Flexible medical fluid container having a combined fill and administration port and reinforced hanger |
US3993223A (en) * | 1974-07-25 | 1976-11-23 | American Home Products Corporation | Dispensing container |
US4150744A (en) * | 1976-02-27 | 1979-04-24 | Smith & Nephew Pharmaceuticals Ltd. | Packaging |
US3994412A (en) * | 1976-03-11 | 1976-11-30 | Abbott Laboratories | Tamperproof breakaway port |
US4201208A (en) * | 1977-11-30 | 1980-05-06 | Abbott Laboratories | Sterile connecting device |
US4654240A (en) | 1984-09-28 | 1987-03-31 | Baxter Travenol Laboratories, Inc. | Laminate film for flexible containers |
US5066290A (en) * | 1986-02-07 | 1991-11-19 | Baxter International Inc. | Sterilizable multi-layer plastic materials for medical containers and the like |
EP0551453B1 (fr) * | 1991-05-08 | 1995-01-18 | Baxter International Inc. | RECIPIENT POUR l'IRRADIATION DES PRODUITS SANGUINS |
EP0605705B1 (fr) | 1992-07-29 | 1997-05-21 | Baxter International Inc. | Recipients pharmaceutiques et dispositifs medicaux ayant des surfaces hydrophiles et compatibles avec les proteines |
US5390796A (en) * | 1992-10-02 | 1995-02-21 | Kerfoot, Jr.; Franklin W. | Envelope apparatus for dispensing medications from drug files |
US5849843A (en) | 1993-11-16 | 1998-12-15 | Baxter International Inc. | Polymeric compositions for medical packaging and devices |
US5998019A (en) | 1993-11-16 | 1999-12-07 | Baxter International Inc. | Multi-layered polymer structure for medical products |
CA2164825C (fr) * | 1994-05-11 | 2006-07-18 | Michel Joie | Systeme de collecte de sang |
US5514106A (en) * | 1994-12-20 | 1996-05-07 | Baxter International Inc. | Bag including an identification system indicative of treatment of the bag |
CA2253852C (fr) * | 1996-05-13 | 2008-06-17 | B. Braun Medical, Inc. | Receptacle pour medicaments flexible et a plusieurs compartiments, et son procede de fabrication et d'utilisation |
US5910138A (en) * | 1996-05-13 | 1999-06-08 | B. Braun Medical, Inc. | Flexible medical container with selectively enlargeable compartments and method for making same |
US5984912A (en) | 1997-07-25 | 1999-11-16 | Brocco Diagnostics, Inc. | Collapsible medical bag for the containment and delivery of diagnostic contrast media and parenteral drug formulations |
US6764481B1 (en) * | 1997-10-27 | 2004-07-20 | Otsuka Pharmaceutical Factory, Inc. | Packaged ophthalmic perfusate and cleaning fluid bag |
US6183460B1 (en) * | 1998-01-22 | 2001-02-06 | Baxter International Inc. | Multi-use solution container having flaps |
TW367247B (en) * | 1998-02-03 | 1999-08-21 | Otsuka Pharma Co Ltd | Storage container for Vitamin D solution and transfusion container |
US5896989A (en) * | 1998-02-20 | 1999-04-27 | Bracco Research Usa | Flexible medical container packaging |
US20020056989A1 (en) | 1998-04-02 | 2002-05-16 | Lewis-Leander | Medication i.v. warning label |
US6267745B1 (en) * | 1998-05-21 | 2001-07-31 | Baxter International Inc. | Confined air tube and methods for handling air in closed blood processing systems |
US6200300B1 (en) * | 1998-11-18 | 2001-03-13 | David S. Smith Packaging Limited | Hangable container |
JP3607103B2 (ja) * | 1998-12-14 | 2005-01-05 | 株式会社大塚製薬工場 | 多層フィルムおよび容器 |
US7025877B1 (en) * | 1999-06-03 | 2006-04-11 | Baxter International Inc. | Processing set for processing and treating a biological fluid |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
GB2358386B (en) * | 1999-11-25 | 2004-04-07 | Zeal Medical | Flexible storage containers for blood platelets |
US6199698B1 (en) * | 1999-12-03 | 2001-03-13 | Alusuisse Technology & Management, Ltd. | Pharmaceutical packaging with separation means |
US6613036B1 (en) * | 2000-02-01 | 2003-09-02 | Abbott Laboratories | Light-protective container assembly and method of making same |
US7243689B2 (en) * | 2000-02-11 | 2007-07-17 | Medical Instill Technologies, Inc. | Device with needle penetrable and laser resealable portion and related method |
GB2359386B (en) | 2000-02-16 | 2004-08-04 | Data Connection Ltd | Replicated control block handles for fault-tolerant computer systems |
US20010047162A1 (en) * | 2000-02-17 | 2001-11-29 | Yasumi Yugari | Injection kit and injection device |
US6328082B1 (en) * | 2000-03-07 | 2001-12-11 | Bbtresor Inc. | Disposable sterile bag, e.g. for breast milk |
US6723076B1 (en) * | 2000-03-24 | 2004-04-20 | Michael Strobel | Animal drug delivery device |
US20020124526A1 (en) * | 2001-03-12 | 2002-09-12 | Lewis James D. | Albumin in a flexible polymeric container |
EP1245217B1 (fr) * | 2001-03-27 | 2009-10-28 | Nipro Corporation | Récipient en matière plastique contenant une solution d'albumine |
KR20030097834A (ko) | 2001-04-18 | 2003-12-31 | 노쓰필드 라보라토리스, 인코포레이티드 | 안정화된 헤모글로빈 용액을 저장하기 위한 가요성 용기시스템 |
FR2824568B1 (fr) | 2001-05-11 | 2004-04-09 | Lab Francais Du Fractionnement | Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique |
US6845883B2 (en) * | 2001-10-18 | 2005-01-25 | Kenneth H. Pieri | Toothpaste dispenser |
US8839538B2 (en) * | 2001-11-02 | 2014-09-23 | Quality Assured Enterprises, Inc. | Tube container with an integral accessory panel |
JP2003135563A (ja) * | 2001-11-02 | 2003-05-13 | Nipro Corp | 小型の袋状薬剤容器 |
US6786515B2 (en) * | 2001-11-02 | 2004-09-07 | Quality Assured Enterprises, Inc. | Tube container with an integral panel for carrying a label |
JP2007536068A (ja) * | 2003-02-13 | 2007-12-13 | アイエルシー ドーヴァー、エルピー | 使い捨て可能な可撓性容器 |
US20050085785A1 (en) * | 2003-10-17 | 2005-04-21 | Sherwin Shang | High impact strength film and non-pvc containing container and pouch and overpouch |
US7264582B2 (en) * | 2004-03-11 | 2007-09-04 | 2004Adploy Limited Partnership | Pouch containers having advertising media and methods for their dissemination |
DE202004012986U1 (de) * | 2004-08-19 | 2004-10-14 | Anton Debatin GmbH Werk für werbende Verpackung | Sicherheitsbeutel |
FR2874816B1 (fr) * | 2004-09-08 | 2006-12-08 | Guerbet Sa | Ensemble de stockage pour produits de contraste |
US7297384B2 (en) | 2004-12-07 | 2007-11-20 | Shawn Kelly Crowley | Metallized heat resistant material with thermal barrier |
EP1836099B1 (fr) * | 2004-12-20 | 2010-07-28 | Bharat Petroleum Corporation Limited | Moule pour le conditionnement de bitume |
US8338093B2 (en) | 2004-12-31 | 2012-12-25 | Affymetrix, Inc. | Primer array synthesis and validation |
WO2006091610A2 (fr) * | 2005-02-23 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Inhibiteurs de l'infectiosite des virus enveloppes |
US8354249B2 (en) * | 2005-08-11 | 2013-01-15 | Omrix Biopharmaceuticals Ltd. | Intravenous immunoglobulin composition |
FR2895263B1 (fr) | 2005-12-26 | 2008-05-30 | Lab Francais Du Fractionnement | Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives |
ATE506080T1 (de) * | 2006-02-28 | 2011-05-15 | Novo Nordisk As | Verfahren zur strahlungs-sterilisation von kunststoff-verpackungsmaterial für insulin |
CA2647030C (fr) * | 2006-03-09 | 2016-10-25 | 3M Innovative Properties Company | Dispositif de distribution d'un materiau |
JP2007236757A (ja) * | 2006-03-10 | 2007-09-20 | Hosokawa Yoko Co Ltd | 輸液バッグ包装体および包装袋 |
CN2882604Y (zh) | 2006-03-31 | 2007-03-28 | 湖南千山制药机械股份有限公司 | 带独立标签及装药接口的输液袋 |
CN101506358B (zh) * | 2006-05-15 | 2013-07-17 | 免疫医学股份有限公司 | 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物 |
EP2033615B1 (fr) * | 2006-06-28 | 2017-05-10 | Fujimori Kogyo Co., Ltd. | Récipient pour liquide |
EP2102003A2 (fr) * | 2006-10-18 | 2009-09-23 | Tekni-Plex Europe, Naamloze Vennootschap | Procédé de fabrication d'une pellicule multicouche et pellicule fabriquée selon ce procédé |
US7776022B2 (en) * | 2007-03-19 | 2010-08-17 | Hemcon Medical Technologies | Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma |
US20090223080A1 (en) * | 2007-03-19 | 2009-09-10 | Hemcon Medical Technologies, Inc. | Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma |
US20090036862A1 (en) * | 2007-08-01 | 2009-02-05 | Owens-Ilinois Healthcare Packaging Inc. | Multilayer plastic container and method of storing lyophilized products |
NZ560646A (en) * | 2007-08-14 | 2010-01-29 | Bomac Research Ltd | Treatment apparatus |
KR100847115B1 (ko) | 2007-10-16 | 2008-07-18 | 센트럴메디컬서비스(주) | 수액제 이중포장용기 |
US7918830B2 (en) * | 2007-12-03 | 2011-04-05 | Pharmedium Services, Llc | Safety device for drug delivery devices and containers |
KR101039270B1 (ko) | 2007-12-24 | 2011-06-07 | 제이더블유생명과학 주식회사 | 수액 용기용 다층 필름, 및 이를 구비한 수액 용기 |
AU2008345108A1 (en) * | 2007-12-28 | 2009-07-09 | Aktivpak, Inc. | Dispenser and therapeutic package suitable for administering a therapeutic substance to a subject |
RS52600B (en) | 2008-09-29 | 2013-04-30 | Vifor (International) Ag | THE COURT AND PROCEEDINGS FOR THE STORAGE AND Bringing of Liquid and Liquid Medicinal Products |
US10118758B2 (en) * | 2008-12-22 | 2018-11-06 | Marat Purliyev | Floatable infusion package |
-
2009
- 2009-08-24 FR FR0904031A patent/FR2949195B1/fr not_active Expired - Fee Related
-
2010
- 2010-08-23 CA CA2771736A patent/CA2771736A1/fr not_active Abandoned
- 2010-08-23 US US13/392,013 patent/US9468585B2/en not_active Expired - Fee Related
- 2010-08-23 DK DK10752431.6T patent/DK2470147T3/en active
- 2010-08-23 CN CN2010800379107A patent/CN102548522A/zh active Pending
- 2010-08-23 EP EP10752431.6A patent/EP2470147B1/fr not_active Not-in-force
- 2010-08-23 WO PCT/IB2010/053786 patent/WO2011024112A1/fr active Application Filing
- 2010-08-23 EP EP15188993.8A patent/EP3000457A1/fr not_active Withdrawn
- 2010-08-23 KR KR1020127007551A patent/KR20120048693A/ko not_active Application Discontinuation
- 2010-08-23 PL PL10752431T patent/PL2470147T3/pl unknown
- 2010-08-23 BR BR112012004006-5A patent/BR112012004006A2/pt not_active Application Discontinuation
- 2010-08-23 AU AU2010288193A patent/AU2010288193A1/en not_active Abandoned
- 2010-08-23 ES ES10752431.6T patent/ES2558529T3/es active Active
-
2012
- 2012-02-15 IL IL218133A patent/IL218133A0/en unknown
-
2016
- 2016-08-31 US US15/253,327 patent/US10342734B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of WO2011024112A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2010288193A1 (en) | 2012-03-08 |
PL2470147T3 (pl) | 2016-03-31 |
CN102548522A (zh) | 2012-07-04 |
WO2011024112A1 (fr) | 2011-03-03 |
DK2470147T3 (en) | 2016-01-25 |
KR20120048693A (ko) | 2012-05-15 |
FR2949195A1 (fr) | 2011-02-25 |
CA2771736A1 (fr) | 2011-03-03 |
US9468585B2 (en) | 2016-10-18 |
FR2949195B1 (fr) | 2011-10-14 |
US10342734B2 (en) | 2019-07-09 |
BR112012004006A2 (pt) | 2018-03-20 |
ES2558529T3 (es) | 2016-02-05 |
US20120145580A1 (en) | 2012-06-14 |
EP2470147B1 (fr) | 2015-10-14 |
EP3000457A1 (fr) | 2016-03-30 |
US20180049946A1 (en) | 2018-02-22 |
IL218133A0 (en) | 2012-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2470147B1 (fr) | Poche de stockage de solution therapeutique | |
EP1909739B1 (fr) | Contenant a chambres multiples | |
CN104528165B (zh) | 用于氧敏感药物的包装系统 | |
AU2015380381B2 (en) | Process for manufacturing glatiramer acetate product | |
JP4984228B2 (ja) | 注出具付き包装袋およびその製造方法 | |
JP2002325823A (ja) | 酸素感受性薬剤の一回服用量投薬 | |
JP4607609B2 (ja) | 薬液バッグ、薬液バッグ収容体および薬液バッグ収容体の製造方法 | |
CA2396772A1 (fr) | Ensemble receptacle de protection contre la lumiere et son procede de fabrication | |
JPH11276550A (ja) | 柔軟な医薬品容器の包装 | |
EP2702976B1 (fr) | Récipient pour l'administration d'un médicament | |
EP1799174B1 (fr) | Ensemble de stockage pour produits de contraste. | |
FR3050931A1 (fr) | Dispositif et procede d'emballage de medicaments solides, dispositif de stockage et de distribution de tels medicaments et procede de distribution | |
RU2381103C2 (ru) | Контейнер для жидких фармацевтических композиций с высокими влагозащитными свойствами | |
EP1894000A2 (fr) | Procédé pour la détermination d'une contamination pathogène dans un fluide contenant des plaquettes sanguines | |
WO2000021527A2 (fr) | Conditionnement d'une preparation d'oxaliplatine | |
FR2901047A1 (fr) | Etiquette destinee a etre jointe a des produits pharmaceutiques, parapharmaceutiques, phitosanitaires et similaires | |
FR2591101A1 (fr) | Conteneur aplatissable et souple pour prelevement et/ou administration de liquides biologiques comportant des moyens d'identification de la provenance et/ou de la destination des susdits liquides. | |
CN108697577A (zh) | 包装多单剂量容器 | |
WO2003002139A1 (fr) | Procede permettant d'ameliorer la stabilite de la preparation de proteines | |
WO2009094854A1 (fr) | Conditionnement extérieur comprenant un film d'aluminium composite pour perfusion médicale contenue dans une poche non formée de pvc | |
Buchanan | 2 Sterile Preparation Formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120326 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20130703 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOT |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150429 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 754578 Country of ref document: AT Kind code of ref document: T Effective date: 20151015 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: FRENCH |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010028258 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: WEINMANN ZIMMERLI, CH |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20160118 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2558529 Country of ref document: ES Kind code of ref document: T3 Effective date: 20160205 Ref country code: DE Ref legal event code: R082 Ref document number: 602010028258 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160114 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160214 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160215 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160115 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R026 Ref document number: 602010028258 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
26 | Opposition filed |
Opponent name: BAXALTA GMBH Effective date: 20160714 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 |
|
PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160823 |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 754578 Country of ref document: AT Kind code of ref document: T Effective date: 20151014 |
|
R26 | Opposition filed (corrected) |
Opponent name: BAXALTA GMBH Effective date: 20160714 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R100 Ref document number: 602010028258 Country of ref document: DE |
|
PLCK | Communication despatched that opposition was rejected |
Free format text: ORIGINAL CODE: EPIDOSNREJ1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20100823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 |
|
PLBN | Opposition rejected |
Free format text: ORIGINAL CODE: 0009273 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: OPPOSITION REJECTED |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 |
|
27O | Opposition rejected |
Effective date: 20180116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20151014 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20190726 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20190722 Year of fee payment: 10 Ref country code: DK Payment date: 20190726 Year of fee payment: 10 Ref country code: ES Payment date: 20190902 Year of fee payment: 10 Ref country code: SE Payment date: 20190726 Year of fee payment: 10 Ref country code: FR Payment date: 20190722 Year of fee payment: 10 Ref country code: DE Payment date: 20190722 Year of fee payment: 10 Ref country code: TR Payment date: 20190805 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20190725 Year of fee payment: 10 Ref country code: PL Payment date: 20190724 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20190722 Year of fee payment: 10 Ref country code: AT Payment date: 20190724 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20190722 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602010028258 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20200831 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20200901 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 754578 Country of ref document: AT Kind code of ref document: T Effective date: 20200823 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20200823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200831 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20200831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200823 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200824 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210302 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200831 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200823 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200831 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200901 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20220110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200824 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200823 |